Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2
Jyoti Nangalia, Charles Massie, E. Joanna Baxter, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 25, pp. 2391-2405
Open Access | Times Cited: 1647

Showing 1-25 of 1647 citing articles:

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
Anand Padmanabhan, Laura Connelly‐Smith, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2019) Vol. 34, Iss. 3, pp. 171-354
Closed Access | Times Cited: 2092
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie, Charles Lu, Jiayin Wang, et al.
Nature Medicine (2014) Vol. 20, Iss. 12, pp. 1472-1478
Open Access | Times Cited: 1724
SC3: consensus clustering of single-cell RNA-seq data
Vladimir Yu Kiselev, Kristina Kirschner, Michael T. Schaub, et al.
Nature Methods (2017) Vol. 14, Iss. 5, pp. 483-486
Open Access | Times Cited: 1360
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Nature reviews. Cancer (2021) Vol. 21, Iss. 5, pp. 298-312
Closed Access | Times Cited: 983
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal, Benjamin L. Ebert
Science (2019) Vol. 366, Iss. 6465
Open Access | Times Cited: 835
EASL Clinical Practice Guidelines: Vascular diseases of the liver

Journal of Hepatology (2015) Vol. 64, Iss. 1, pp. 179-202
Closed Access | Times Cited: 703
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, et al.
Blood (2014) Vol. 124, Iss. 16, pp. 2507-2513
Open Access | Times Cited: 669
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue
Joseph E. Schwartz, Anand Padmanabhan, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2016) Vol. 31, Iss. 3, pp. 149-338
Closed Access | Times Cited: 669
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz, Jeffrey L. Winters, Anand Padmanabhan, et al.
Journal of Clinical Apheresis (2013) Vol. 28, Iss. 3, pp. 145-284
Closed Access | Times Cited: 581
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg, Axel Karow, Ronny Nienhold, et al.
Blood (2014) Vol. 123, Iss. 14, pp. 2220-2228
Open Access | Times Cited: 577
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Sally Thomas, John A. Snowden, Martin P. Zeidler, et al.
British Journal of Cancer (2015) Vol. 113, Iss. 3, pp. 365-371
Open Access | Times Cited: 572
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi, Daniela Pietra, Virginia Valeria Ferretti, et al.
Blood (2013) Vol. 123, Iss. 10, pp. 1544-1551
Open Access | Times Cited: 549
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, et al.
Blood Cancer Journal (2018) Vol. 8, Iss. 2
Open Access | Times Cited: 543
Effect of Mutation Order on Myeloproliferative Neoplasms
Christina A. Ortmann, David G. Kent, Jyoti Nangalia, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 7, pp. 601-612
Open Access | Times Cited: 533
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics
Blood (2016) Vol. 129, Iss. 6, pp. 667-679
Open Access | Times Cited: 531
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Jacob Grinfeld, Jyoti Nangalia, E. Joanna Baxter, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 15, pp. 1416-1430
Open Access | Times Cited: 528
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
Ayalew Tefferi, Terra L. Lasho, Christy Finke, et al.
Leukemia (2014) Vol. 28, Iss. 7, pp. 1472-1477
Closed Access | Times Cited: 523
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, et al.
Leukemia (2018) Vol. 32, Iss. 5, pp. 1057-1069
Open Access | Times Cited: 491
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Lorena Arranz, Abel Sánchez‐Aguilera, Daniel Martín-Pérez, et al.
Nature (2014) Vol. 512, Iss. 7512, pp. 78-81
Closed Access | Times Cited: 414
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Animesh Pardanani, Claire Harrison, Jorge E. Cortés, et al.
JAMA Oncology (2015) Vol. 1, Iss. 5, pp. 643-643
Closed Access | Times Cited: 412
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno, Carmela Mannarelli, Paola Guglielmelli, et al.
Blood (2013) Vol. 123, Iss. 10, pp. 1552-1555
Open Access | Times Cited: 394
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit K. Rampal, Fátima Al‐Shahrour, Omar Abdel‐Wahab, et al.
Blood (2014) Vol. 123, Iss. 22, pp. e123-e133
Open Access | Times Cited: 379
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Blood (2014) Vol. 124, Iss. 7, pp. 1062-1069
Open Access | Times Cited: 366
Paroxysmal nocturnal haemoglobinuria
Anita Hill, Amy E. DeZern, Taroh Kinoshita, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Open Access | Times Cited: 364
Myeloproliferative Neoplasms
Jerry L. Spivak
New England Journal of Medicine (2017) Vol. 376, Iss. 22, pp. 2168-2181
Closed Access | Times Cited: 335
Page 1 - Next Page

Scroll to top